Valuation: Atossa Therapeutics, Inc.

Market Cap 26.35M 22.58M 21.12M 19.31M 36.44M 2.52B 36.83M 250M 97.19M 1.27B 98.92M 96.78M 4.19B P/E 2026 *
-0.69x
P/E 2027 * -0.84x
Enterprise Value 26.35M 22.58M 21.12M 19.31M 36.44M 2.52B 36.83M 250M 97.19M 1.27B 98.92M 96.78M 4.19B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+3.94%
1 week-5.38%
Current month+27.54%
1 month+15.03%
3 months-46.77%
6 months-37.29%
Current year-70.17%
1 week 2.44
Extreme 2.44
2.76
1 month 2.05
Extreme 2.05
2.97
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
64.65
10 years 1.7
Extreme 1.7
694.8
Manager TitleAgeSince
Chief Executive Officer 75 01/04/2009
Director of Finance/CFO 50 14/10/2025
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Chairman 75 01/04/2009
Director/Board Member 64 01/04/2009
Director/Board Member 79 01/07/2011
Date Insider Type Main position Quantity % Market Cap.
20/1/26 Free

Chief Executive Officer

1,281,674 0.9922%
20/1/26
Ensisheim Partners LLC
OtherCompany 0 0%
14/10/25 Free

Chief Financial Officer

578,000 0.4595%
Change 5-day change 1-year change 3-year change Capi.($)
+3.94%-5.38%-77.36%-79.88% 26.35M
+0.95%+4.70%+3.42%+25.16% 51.21B
+1.01%-0.20%+471.68%+564.93% 45.35B
+0.16%+7.88%+36.14%+20.76% 42.84B
-0.66%+2.61%+18.59%+87.04% 42.29B
+0.88%-3.48%+17.20%+53.83% 32.15B
-0.12%+3.84%+33.73%+145.25% 17.31B
-0.53%+1.84% - - 16.55B
+0.49%+5.60%+10.22%+31.69% 14.84B
+1.15%+4.17%+84.49%+50.33% 14.25B
Average +0.72%+2.37%+66.46%+99.90% 27.68B
Weighted average by Cap. +0.41%+3.07%+101.40%+141.81%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -29.9M -27.97M -25.58M -48.26M -3.34B -48.78M -331M -129M -1.68B -131M -128M -5.55B -38.03M -32.59M -30.49M -27.87M -52.6M -3.64B -53.16M -361M -140M -1.83B -143M -140M -6.05B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
24/08/26 US$2.640 +3.94% 57,149
21/08/26 US$2.540 -1.93% 25,656
20/08/26 US$2.590 -1.89% 70,954
19/08/26 US$2.640 +1.93% 62,197
18/08/26 US$2.590 -7.17% 58,563
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.640USD
Average target price
18.67USD
Spread / Average Target
+607.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock